Results 41 to 50 of about 10,096 (205)

Age related gene DST represents an independent prognostic factor for MYCN non-amplified neuroblastoma

BMC Pediatrics, 2021
Background MYCN amplification and age are two critical prognostic factors of pediatric neuroblastoma. Previously, we had revealed the prognosis of MYCN target genes.
Haiwei Wang, Xinrui Wang, Liangpu Xu, Ji Zhang, Hua Cao   +4 more
doaj   +1 more source

Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study. [PDF]

Br J Cancer, 2018
In neuroblastoma (NB), the most powerful prognostic marker, the MYCN amplification (MNA), occasionally shows intratumoural heterogeneity (ITH), i.e. coexistence of MYCN-amplified and non-MYCN-amplified tumour cell clones, called heterogeneous MNA (hetMNA).
Berbegall AP, Bogen D, Pötschger U, Beiske K, Bown N, Combaret V, Defferrari R, Jeison M, Mazzocco K, Varesio L, Vicha A, Ash S, Castel V, Coze C, Ladenstein R, Owens C, Papadakis V, Ruud E, Amann G, Sementa AR, Navarro S, Ambros PF, Noguera R, Ambros IM.   +23 more
europepmc   +8 more sources

MYCN mRNA degradation and cancer suppression by a selective small-molecule inhibitor in MYCN-amplified neuroblastoma

Frontiers in Oncology, 2022
Amplification of the MYCN gene leads to its overexpression at both the mRNA and protein levels. Overexpression of MYCN mRNA may also have an important role in promoting neuroblastoma (NB) beyond the translation of MYCN protein.
Tao Liu, Lubing Gu, Zhongzhi Wu, Najah Albadari, Wei Li, Muxiang Zhou   +5 more
doaj   +1 more source

Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma [PDF]

Nature Genetics, 2018
Amplification of the locus encoding the oncogenic transcription factor MYCN is a defining feature of high-risk neuroblastoma. Here we present the first dynamic chromatin and transcriptional landscape of MYCN perturbation in neuroblastoma. At oncogenic levels, MYCN associates with E-box binding motifs in an affinity-dependent manner, binding to strong ...
Rhamy Zeid, Matthew A. Lawlor, Evon Poon, Jaime M. Reyes, Mariateresa Fulciniti, Michael A. Lopez, Thomas G. Scott, Behnam Nabet, Michael A. Erb, Georg E. Winter, Zoe Jacobson, Donald R. Polaski, Kristen L. Karlin, Rachel A. Hirsch, Nikhil P. Munshi, Thomas F. Westbrook, Louis Chesler, Charles Y. Lin, James E. Bradner   +18 more
openaire   +3 more sources

Chromosome 1p36 candidate gene ZNF436 predicts the prognosis of neuroblastoma: a bioinformatic analysis

Italian Journal of Pediatrics, 2023
Background Genetic 1p deletion is reported in 30% of all neuroblastoma and is associated with the unfavorable prognosis of neuroblastoma. The expressions and prognosis of 1p candidate genes in neuroblastoma are unclear.
Haiwei Wang, Xinrui Wang, Liangpu Xu
doaj   +1 more source

Clinically aggressive pediatric spinal ependymoma with novel MYC amplification demonstrates molecular and histopathologic similarity to newly described MYCN-amplified spinal ependymomas

Acta Neuropathologica Communications, 2021
Primary spinal cord tumors contribute to ≤ 10% of central nervous system tumors in individuals of pediatric or adolescent age. Among intramedullary tumors, spinal ependymomas make up ~ 30% of this rare tumor population.
Margaret Shatara, Kathleen M. Schieffer, Darren Klawinski, Diana L. Thomas, Christopher R. Pierson, Eric A. Sribnick, Jeremy Jones, Diana P. Rodriguez, Carol Deeg, Elizabeth Hamelberg, Stephanie LaHaye, Katherine E. Miller, James Fitch, Benjamin Kelly, Kristen Leraas, Ruthann Pfau, Peter White, Vincent Magrini, Richard K. Wilson, Elaine R. Mardis, Mohamed S. Abdelbaki, Jonathan L. Finlay, Daniel R. Boué, Catherine E. Cottrell, David R. Ghasemi, Kristian W. Pajtler, Diana S. Osorio   +26 more
doaj   +1 more source

Correlation Between MYCN Gene Status and MYCN Protein Expression in Neuroblastoma: A Pilot Study To Propose the Use of MYCN Immunohistochemistry in Limited-Resource Areas

Journal of Global Oncology, 2019
PURPOSE: The most significant adverse risk factor for neuroblastoma (NB) is MYCN gene amplification, which strongly associates with high-risk disease.
Teresa Santiago, Nidale Tarek, Fouad Boulos, Caleb Hayes, Sima Jeha, Susana Raimondi, Carlos Rodriguez-Galindo   +6 more
doaj   +1 more source

The potential molecularly therapy target to MYCN‐amplificated neuroblastoma

Clinical and Translational Discovery, 2023
AbstractNeuroblastoma (NB) is an embryonal deadly cancer in childhood driven by MYC or MYCN‐driven oncogenic signaling. The amplification of MYCN leads to malignant progression of NB and poor prognosis. Traditional chemotherapy is still a standard treatment for NB. Most of the cytostatic drugs take function in anti‐neuroblastoma. However, children with
Susu Jiang, Xinxin Zhang, Jiaming Chang, Jinhong Zhu, Wenhan Yang, Jing He   +5 more
openaire   +2 more sources

Copy number gain of MYCN gene is a recurrent genetic aberration and favorable prognostic factor in Chinese pediatric neuroblastoma patients

Diagnostic Pathology, 2013
Background Amplification of MYCN oncogene is an established marker indicating aggressive tumor progression of neuroblastoma (NBL). But copy number analyses of MYCN gene in ganglioneuroblastoma (GNBL) and ganglioneuroma(GN) is poorly described in the ...
Wang Miao, Zhou Chunju, Cai Rongqin, Li Yong, Gong Liping   +4 more
doaj   +1 more source

Regulation of MYCN expression in human neuroblastoma cells

BMC Cancer, 2009
Background Amplification of the MYCN gene in neuroblastoma (NB) is associated with a poor prognosis. However, MYCN-amplification does not automatically result in higher expression of MYCN in children with NB.
de Vries I, Hulsbergen-van de Kaa Christina A, van Leeuwen Frank N, van Bokhoven Hans, Jacobs Joannes FM, Adema Gosse J, Hoogerbrugge Peter M, de Brouwer Arjan PM   +7 more
doaj   +1 more source